Executive Summary

Psoriasis is an incurable skin disease that is characterized by rapid cell proliferation and inflammation. It effects 3% of the world’s population, and The Medical Technology Stock Letter estimates the global market for psoriasis therapies to exceed $7 billion annually. Current treatments are primarily topical creams and ointments, most of which have side effects or safety concerns that preclude long-term use.

Recent developments in the area of biotech psoriasis research has been directed towards developing treatment only for the most severe form of the disease This will leave the 8 million North Americans suffering from mild to moderate psoriasis, and their dermatologists, still seeking something new.

The market for a new treatment for mild to moderate psoriasis, which combines the right level of safety and efficacy, and allows for long-term use, is vast and growing everyday.

GOOD NEWS - Three years of scientific research, clinical trials and product development, has Prime in a position to launch a unique, highly effective, non-irritating psoriasis treatment that delivers superior results with virtually no side effects or risks to the patient.

Prime’s treatment, Reliéva®, meets all North American regulatory requirements and is now ready for distribution.

Reliéva® is a safe and effective treatment that can be obtained without a prescription and is used on its own or in combination with other products. This makes Reliéva® a treatment alternative for all psoriasis sufferers.

Plants have long been the source of many active ingredients found in pharmaceuticals. Aspirin, likely the most well known, was originally formulated by extracting salacin from the bark of the willow tree.

Like aspirin, Reliéva® also derives its effectiveness from an active ingredient found in a plant extract. Combining scientific developments from both university and industry based experts; Prime has created a new extraction process designed to maximize the concentration of targeted active ingredients within plant extracts thereby vastly improving product effectiveness.

Reliéva® was created by formulating this unique plant extract within a “state of the art” biotech topical delivery system to further enhance the effectiveness of the product.

Prime is proceeding with a combination patent application covering both the extraction process and the micro-encapsulation of the extract.

The corporation is in a position to fuel significant growth well beyond the introduction of Reliéva®, based on its scientific intellectual property and patented technologies.

Prime’s unique extraction process presents promising out-licensing opportunities, as it will allow other plant-based manufacturers to enhance their extracts.

The company has acquired the Canadian license to the dermatological use of a new class of antioxidant compounds, Azeul Nitrones, which hold great promise of slowing down the negative results of ageing skin.

Prime owns the worldwide rights to a breakthrough micro-sphere particle technology for dermatological and cosmetic applications. This technology has many advantages over other biotechnology delivery systems used in topical formulations and can offer improvements to many existing pharmaceuticals and cosmetics as well as make possible the formulation of new and more effective treatments.

Prime is financing a joint biotech research program with Memorial University in Newfoundland, which is focused on creating a new molecule that is effective in treating skin, and other diseases, that are characterized by inflammation and rapid cell proliferation. In recent history, new molecules that result in new drugs such as Tiazac (Biovail) An-1792 (Elan), Viagra (Pfizer), and Celexa (Forest Labs) have proven to be of significant commercial success.

Prime has ensured a long-term source of scientific technology through a strategic alliance with Utek Corporation, a Florida based, technology transfer company. Utek (UTK) is a public company listed on the American Stock Exchange, which has entered into an agreement whereby they will source and introduce appropriate technology acquisition opportunities for Prime. Utek, with its advisory board of 18 scientists, of which 3 are Nobel prizewinners, has recognized the huge potential of Prime Pharmaceutical Corporation and made a substantial equity investment in the company.

Over the past three years, Prime Pharmaceutical Corporation has assembled all the components necessary to build a world-class dermatology company. The management team has an impressive history of success in the dermatological arena and forms a committed and energetic foundation for Prime. The company is prepared to launch a major new treatment that will significantly improve the quality of life for millions of psoriasis sufferers while capitalizing on a huge market opportunity. Prime has put together unparalleled scientific and manufacturing affiliations for ongoing research and product development, which combined with key intellectual property and technologies, will ensure ongoing corporate growth.

The company will seek to become public by way of an amalgamation or filing of an I.P.O. in order to maximize the value for it’s shareholder base.